Modality
Bispecific Ab
MOA
FcRni
Target
IL-17A
Pathway
mTOR
SchizophreniaMDS
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
~Oct 2018
→ ~Jan 2020
Phase 3
Apr 2020
→ Aug 2025
Phase 3Current
NCT06215842
107 pts·Schizophrenia
2020-04→2025-08·Active
107 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-227mo agoPh3 Readout· Schizophrenia
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P3
Active
Catalysts
Ph3 Readout
2025-08-22 · 7mo ago
Schizophrenia
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06215842 | Phase 3 | Schizophrenia | Active | 107 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA |